Vemurafenib is a targeted therapy medication primarily used to treat patients with BRAF V600E mutation-positive metastatic melanoma, a type of skin cancer. It works by inhibiting the activity of the mutated BRAF protein, which plays a crucial role in cancer cell growth and division. By blocking this protein, vemurafenib helps slow down or stop the progression of the disease. Approved by the U.S. Food and Drug Administration (FDA) in 2011, vemurafenib is often prescribed for patients who have not responded to other treatments. It is typically taken as an oral tablet and may be used in combination with other therapies to enhance its effectiveness. Regular monitoring is essential to manage potential side effects.